[Proteomics and breast cancer: new perspectives and limitations].
From differential analysis for the identification of biomarkers, to functional analysis for the evidencing of new therapeutic targets, proteomics brings new comprehensive information for a better understanding of the molecular basis of oncology and new perspectives for the clinic. However the major limitation of proteomic investigations and more generally of post-genomic approaches remains the molecular and cellular complexity of biological systems. This will be illustrated with the case of breast cancer.
Hondermarck
H
H
ERI-8 Inserm << signalisation des facteurs de croissance dans le cancer du sein >>, IFR-118, université des sciences et technologies de Lille, Villeneuve d'Ascq, France. hubert.hondermarck@univ-lillel.fr
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D005260:Female; D006801:Humans; D009363:Neoplasm Proteins / Q000187:drug effects*; D040901:Proteomics
D000970:Antineoplastic Agents; D009363:Neoplasm Proteins